ARTIFICIAL CELL evolves into nanomedicine, biotherapeutics, blood substitutes, drug delivery, enzyme/gene therapy, cancer therapy, cell/stem cell therapy, nanoparticles, liposomes, bioencapsulation, replicating synthetic cells, cell encapsulation/scaffold, biosorbent/immunosorbent haemoperfusion/plasmapheresis, regenerative medicine, encapsulated microbe, nanobiotechnology, nanotechnology
Source abstract
Abstract
It is only in the last 20 years that many of the original ideas on artificial cells are being increasingly applied and extended by researchers around the world. Artificial cell has now evolved into nanomedicine, biotherapeutics, blood substitutes, drug delivery, enzyme/gene therapy, cancer therapy, cell/stem cell therapy, nanoparticles, liposomes, bioencapsulation, replicating synthetic cells, cell encapsulation/scaffold, biosorbent/immunosorbent haemoperfusion/plasmapheresis, regenerative medicine, encapsulated microbe, nanobiotechnology, nanotechnology and other areas. More futuristic research includes nanorobot, nanocomputer, multimodal locomotion delivery robot and others. This review starts with a general overview followed by specific examples in more details.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Electrohydrodynamics and Fluid Dynamics · Pancreatic function and diabetes · Molecular Communication and Nanonetworks
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Artificial Cells and Organs Research Centre, Departments of Physiology, Medicine and Biomedical Engineering, Faculty of Medicine, McGill University
References (89)
Show source-provided references
1. Chang, TMS. Haemoglobin corpuscles. Report of a research project for Honours Physiology, Medical Library, McGill University. Also reprinted 1988 as part of “30th Anniversary in Artificial Red Blood Cells Research. Biomater Artif Cells Artif Organs 1957;16:1–9.
2. 10.1126/science.146.3643.52410.1126/science.146.3643.524 ↗
3. 10.1038/218243a010.1038/218243a0 ↗
4. 10.1038/229117a010.1038/229117a0 ↗
5. Chang TMS. Semipermeable aqueous microcapsules “artificial cells”: with emphasis on experiments in an extracorporeal shunt system. Trans Am Soc Artif Intern Organs 1966;12:13–19.
6. Chang TMS. Artificial cells. Springfield, IL: Charles C. Thomas; 1972.
7. 10.1016/S0006-291X(71)80260-710.1016/S0006-291X(71)80260-7 ↗
8. 10.1038/nrd165910.1038/nrd1659 ↗
9. 10.1142/639510.1142/6395 ↗
10. Chang TMS, editor. Selected topics in nanomedicine. London: World Science Publisher/Imperial College Press; 2014.
11. Chang E, Nicolaev T, Zheng, et al. editors. Haemoperfusion and plasma-perfusion and other clinical uses of general, biospecific, immune and leucocyte adsorbents. London: World Scientific Publisher/Imperial College Press; 2017. p. 1004 www.medicine.mcgill.ca/artcell/HPBk_Ch1.pdf
12. Chang TMS. ARTIFICIAL CELLS: biotechnology, nanotechnology, blood substitutes, regenerative medicine, bioencapsulation, cell/stem cell therapy. London: World Scientific Publisher/Imperial College Press; 2019.
13. Chang TMS, Coffey JF, Barre P, et al. Microcapsule artificial kidney: treatment of patients with acute drug intoxication. Can Med Assoc J. 1973;108:429–433.
14. Chang TMS. Blood compatible coating of synthetic immunoadsorbents. Trans Am Soc Artif Intern Organs 1980;26:546–549.
15. 10.1056/NEJM19810115304030810.1056/NEJM198101153040308 ↗
16. Terman DS, Tavel T, Petty D, et al. Specific removal of antibody by extracorporeal circulation over antigen immobilized in collodion-charcoal. Clin Exp Immunol. 1977;28:180.
17. 10.1016/S0272-6386(12)80054-010.1016/S0272-6386(12)80054-0 ↗
18. 10.3109/21691401.2016.113849410.3109/21691401.2016.1138494 ↗
19. 10.1001/jama.2009.85610.1001/jama.2009.856 ↗
20. 10.3109/21691401.2015.104755710.3109/21691401.2015.1047557 ↗
21. (b) Winslow RM. editor. Blood substitutes. Amsterdam: Academic Press; 2006.
22. 10.1016/j.jamcollsurg.2008.09.02310.1016/j.jamcollsurg.2008.09.023 ↗
23. (b) Wang L, Liu F, Yan K, et al. Effects of resuscitation with polymerized porcine haemoglobin pPolyHb on haemodynamic stability and oxygen delivery in a rat model of haemorrhagic shock, Artificial Cells. Nanomed Biotechnol. 2017;45:51–57.
24. 10.3109/21691401.2015.102484610.3109/21691401.2015.1024846 ↗
25. Kim HW, Greenburg AG, editors. Haemoglobin-based oxygen carriers as red cell substitutes and oxygen therapeutics. New York, London: Springer; 2014. p.738.
26. 10.1111/trf.1372610.1111/trf.13726 ↗
27. 10.1038/nbt0798-66710.1038/nbt0798-667 ↗
28. 10.1081/BIO-12000272510.1081/BIO-120002725 ↗
29. Ma L, Hsia CJC. Polynitroxylated Hb as a multifunctional therapeutic for critical care and transfusion medicine in selected topics in nanomedicine Singapore, London: World Science Publisher/Imperial College Press; 2013. p.169–194
30. 10.1142/9789814472869_000710.1142/9789814472869_0007 ↗
31. 10.3109/21691401.2014.96455410.3109/21691401.2014.964554 ↗
32. 10.3109/21691401.2015.103547910.3109/21691401.2015.1035479 ↗
33. 10.3109/21691401.2015.111087110.3109/21691401.2015.1110871 ↗
34. 10.1080/21691401.2018.147637510.1080/21691401.2018.1476375 ↗
35. 10.1081/BIO-12002315510.1081/BIO-120023155 ↗
36. 10.1142/9789814472869_000610.1142/9789814472869_0006 ↗
37. 10.1080/1073119060097390710.1080/10731190600973907 ↗
38. 10.1080/21691401.2017.129367610.1080/21691401.2017.1293676 ↗
39. Chang TMS. Biodegradable semipermeable microcapsules containing enzymes, hormones, vaccines, and other biologicals. J Bioeng. 1976;1:25–32.
40. 10.1142/9789814472869_001510.1142/9789814472869_0015 ↗
41. 10.1142/9789814472869_001610.1142/9789814472869_0016 ↗
42. 10.1021/acs.nanolett.6b0397110.1021/acs.nanolett.6b03971 ↗
43. 10.1080/20022727.2017.137355110.1080/20022727.2017.1373551 ↗
44. Abu AOS Chaw C Williams L et al. Lysozyme and DNAse I loaded poly D L lactide-co-caprolactone nanocapsules as an oral delivery system Nature Scientific Reports 03 September; 2018.
45. 10.1016/S0022-2836(65)80093-610.1016/S0022-2836(65)80093-6 ↗
46. 10.1016/0022-5193(68)90163-X10.1016/0022-5193(68)90163-X ↗
47. Gregoriadis G, editor. Drug carriers in biology and medicine. New York: Academic Press, Inc.; 1976.
48. 10.1016/0005-2787(76)90527-X10.1016/0005-2787(76)90527-X ↗
49. 10.1038/nrd163210.1038/nrd1632 ↗
50. 10.2217/imt-2016-014610.2217/imt-2016-0146 ↗
51. 10.3109/21691401.2016.115348310.3109/21691401.2016.1153483 ↗
52. 10.1038/nature2544310.1038/nature25443 ↗
53. 10.1016/0005-2744(74)90154-510.1016/0005-2744(74)90154-5 ↗
54. 10.1016/S0140-6736(89)90939-210.1016/S0140-6736(89)90939-2 ↗
55. 10.1016/0304-4165(86)90281-310.1016/0304-4165(86)90281-3 ↗
56. 10.1097/01.cmr.0000131013.71638.c010.1097/01.cmr.0000131013.71638.c0 ↗
57. 10.4172/2572-0813.100010210.4172/2572-0813.1000102 ↗
58. 10.1182/blood-2006-09-04535110.1182/blood-2006-09-045351 ↗
59. FDA U.S.F.D.A. FDA approves a new treatment for PKU a rare and serious genetic disease; 2018.
60. Kjellstrand C, Borges H, Pru C, et al. On the clinical use of microencapsulated zirconium phosphate-urease for the treatment of chronic uremia. Trans Am Soc Artif Intern Org. 1981;27:24–30.
61. 10.1016/j.ymgme.2018.06.00210.1016/j.ymgme.2018.06.002 ↗
62. 10.1016/j.ymgme.2011.06.01610.1016/j.ymgme.2011.06.016 ↗
63. 10.1007/s10517-012-1727-310.1007/s10517-012-1727-3 ↗
64. 10.1126/science.677662810.1126/science.6776628 ↗
65. 10.1177/03913988860090051510.1177/039139888600900515 ↗
66. 10.1081/BIO-12002540810.1081/BIO-120025408 ↗
67. 10.1016/j.addr.2013.07.01010.1016/j.addr.2013.07.010 ↗
68. 10.3109/1073119910911784710.3109/10731199109117847 ↗
69. 10.1007/BF0292151710.1007/BF02921517 ↗
70. 10.1038/nm0896-88310.1038/nm0896-883 ↗
71. 10.1038/d41586-018-05476-410.1038/d41586-018-05476-4 ↗
72. 10.1081/BIO-12002541210.1081/BIO-120025412 ↗
73. Iqbal U, Westfall S, Prakash S. Novel microencapsulated probiotic blend for use in metabolic syndrome: design and in-vivo analysis. Artificial Cells, Nanomed Biotechnol. 2018;46:1–9.
74. 10.1002/lt.2063510.1002/lt.20635 ↗
75. 10.1007/978-1-4419-5786-3_710.1007/978-1-4419-5786-3_7 ↗
76. 10.1038/srep1688410.1038/srep16884 ↗
77. 10.1088/2057-1976/aacbe110.1088/2057-1976/aacbe1 ↗
78. 10.1016/j.tibtech.2018.03.00810.1016/j.tibtech.2018.03.008 ↗
79. 10.1002/bit.26036030810.1002/bit.260360308 ↗
80. 10.1139/y66-01310.1139/y66-013 ↗
81. 10.1142/9789814472869_001210.1142/9789814472869_0012 ↗
82. 10.1177/03913988860090011310.1177/039139888600900113 ↗
83. 10.1023/A:100676950396810.1023/A:1006769503968 ↗
84. 10.1016/1074-5521(95)90031-410.1016/1074-5521(95)90031-4 ↗
85. 10.1016/S0958-1669(00)00109-910.1016/S0958-1669(00)00109-9 ↗
86. 10.1126/science.aad625310.1126/science.aad6253 ↗
87. Poncelet D Neufeld R. 20th Bioencapsulation Conference. Present status of bioencapsulation; 2012.
88. 10.1162/artl.2009.16.1.1610310.1162/artl.2009.16.1.16103 ↗
89. Chang TMS. 2019 Artificial cells blood substitutes and nanomedicine. available from: www.medicine.mcgill.ca/artcell